1. Introduction

Breast cancer is the most common cancer in females, accounting for around 2.1 million new diagnoses and over 0.6 million deaths annually across the globe [1]. While the stage distribution at diagnosis varies widely across different demographic regions and different ethnicities in the same region, around 60–70% of patients in North America present with axillary lymph node negative disease [2,3]. Likewise, approximately 75–85% of patients have hormone receptor-positive breast cancer, while human epidermal growth factor receptor-2 (HER2) positive and triple negative tumours account for 15–20% and 10–15%, respectively [4].

The multidisciplinary treatment of patients with node negative breast cancer includes surgery, radiation therapy and systemic therapy (chemotherapy, targeted therapy and hormonal agents) [5]. Adjuvant chemotherapy for node negative, HER2-negative breast cancer has evolved over decades from non-anthracycline, non-taxane, alkylator-based regimens, to anthracycline-based regimens, and finally to sequential administration of anthracyclines and taxanes [6–11]. However, long-term serious adverse events associated with anthracyclines, including irreversible cardiotoxicity, myelodysplastic syndromes and therapy-related leukemias, have led researchers to question the benefit-risk ratio of anthracycline-based chemotherapy regimens, especially in those lacking axillary lymph node involvement [12]. As a result, trials evaluating anthracycline-free, taxane-based chemotherapy regimens, including docetaxel and cyclophosphamide (DC), have been conducted [13,14].

The US Oncology (USON) 9735 trial compared four cycles of...
doxorubicin and cyclophosphamide (AC) with four cycles of DC in patients with resected stage I to III breast cancer [13]. Disease free survival (DFS) at a median follow-up of 5.5 years, and subsequently overall survival (OS) after 7-years follow-up, were superior with four cycles of DC [13,15]. Although the control arm represented one of the standard adjuvant chemotherapy regimens at the time, sequential/concurrent anthracycline-taxane (AT) regimens became widely adopted because of improved survival outcomes seen across multiple studies [16]. Subsequently, three clinical trials, collectively referred as anthracyclines in early breast cancer (ABC), compared six cycles of DC with several AT regimens (two of three trials had concurrent taxane- and anthracycline-based chemotherapy, while the third trial allowed either concurrent or sequential regimens) [14]. In an interim analysis at a median follow-up of 3.3 years, six cycles of DC did not meet the prespecified threshold for non-inferiority and the 4-years invasive DFS (iDFS) of AT was significantly different (90.7% vs. 88.2%, \( P = 0.04 \)). However, an exploratory analysis demonstrated that the benefit of AT was driven by patients with triple negative breast cancer and those with regional lymph node involvement, while survival outcomes were similar in hormone receptor-positive and node negative subgroups [14]. Another clinical trial, West German Study PlanB, evaluated the non-inferiority of six cycles of DC with four cycles each of sequential epirubicin/cyclophosphamide and docetaxel [17]. At a median follow-up of five years, the 5-year DFS and OS were non-inferior in the DC arm across all subgroups.

While several guidelines have included DC as an acceptable regimen for adjuvant chemotherapy in patients with HER2 negative node-negative breast cancer [18–21], the optimal number of cycles continues to be a subject of debate. In Alberta, a large province in Canada with a population of over four million residents, four cycles of DC has been used as a standard chemotherapy regimen in node negative breast cancer. The aim of this study was to determine the survival outcomes (iDFS and OS) of patients with node negative, HER2 negative breast cancer treated with four cycle of adjuvant DC and further, to explore associations of clinical characteristics with survival outcomes.

2. Methods

2.1. Study cohort

Patients were retrieved from the Alberta Health Services (AHS) Cancer Control Breast Data Mart (BDM). The BDM is a data repository of all breast cancer patients diagnosed from January 1, 2004 onwards in Alberta and includes information on patient demographics, tumour characteristics, surgical intervention, Cancer Control Alberta clinic visits, systemic therapies administered, and vital status. The information is prospectively collected from various sources including the Alberta Cancer Registry (ACR), the Cancer Centre Electronic Medical Record (ARIA-MO), the Discharge Abstract Database (DAD), and the National Ambulatory Care Reporting System (NACRS).

We included patients diagnosed with HER2-negative, axillary lymph node negative breast cancer diagnosed January 1, 2008 through December 31, 2012, who were prescribed four cycles of adjuvant DC chemotherapy. As in the ABC group of trials [14], for patients with estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive breast cancer, the tumour was pT1c and grade III, or pT2-pT3 with any grade. Patients who were switched to an anthracycline-based regimen after starting DC or who received four cycles of DC for resected locoregional recurrence were excluded.

The conduct and results of our study are reported in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines [22]. Ethics were institutionally approved under the Alberta Research Ethics Community Consensus Initiative [23].

2.2. Clinical variables

The following variables were extracted from the BDM: patient age at diagnosis, gender, first surgical date, use of adjuvant radiotherapy, tumour characteristics (American Joint Committee on Cancer [AJCC] 7th edition stage, histological subtype, modified Bloom-Richardson (MBR) grade, lymphovascular invasion, and status of ER-receptor, PR-receptor and HER2), vital status, date and cause of death if deceased, and date of last contact with AHS or Cancer Control if not deceased. Review of ARIA-MO was completed to obtain: co-morbidities, body mass index (BMI), type of surgery, date of first cycle of DC, number of cycles of DC completed, use of prophylactic granulocyte-colony stimulating factor (G-CSF) and/or antibiotics, and recurrence or new primary cancer diagnosis (date and type). The Charlson comorbidity index (CCI) score was computed from the data on comorbidities [24]. The BMI was categorized according to the World Health Organization (WHO) classification as underweight, normal, overweight and obese [25].

2.3. Outcome measures

The end-points for this study included invasive disease free survival (iDFS) and overall survival (OS). We defined iDFS as time from diagnosis of breast cancer to local, regional or distant recurrence, invasive contralateral breast cancer, second primary cancer.

---

**Abbreviations**

| Abbreviation | Meaning |
|--------------|---------|
| DC           | Docetaxel and Cyclophosphamide |
| HER2         | Human Epidermal growth factor Receptor-2 |
| iDFS         | Invasive Disease Free Survival |
| OS           | Overall Survival |
| HR           | Hazard Ratio |
| CI           | Confidence Interval |
| AT           | Anthracycline and Taxane |
| USON         | United States Oncology |
| AC           | Doxorubicin and Cyclophosphamide |
| ABC          | Anthracyline in early Breast Cancer |
| AHS          | Alberta Health Services |
| BDM          | Breast Data Mart |
| ACR          | Alberta Cancer Registry |
| DAD          | Discharge Abstract Database |
| NACRS        | National Ambulatory Care Reporting System |
| ER           | Estrogen Receptor |
| PR           | Progesterone Receptor |
| STROBE       | Strengthening the Reporting of Observational Studies in Epidemiology |
| AJCC         | American Joint Committee on Cancer |
| MBR          | Modified Bloom Richardson |
| BMI          | Body Mass Index |
| CCI          | Charlson's Comorbidity Index |
| G-CSF        | Granulocyte-Colony Stimulating Factor |
| WHO          | World Health Organization |
(except non-melanoma skin cancer and in-situ cancer), or death due to any cause. The OS was defined as time from diagnosis to death as a result of any cause. The ABC group of trials, the Plan B and the TAILORx studies reported the survival rates at 4, 5 and 9 years, respectively [14,17,26]. We, therefore, estimated iDFS and OS rates at multiple time-points to assess the outcomes in our population to have reference comparisons.

2.4. Statistical analysis

Descriptive statistics were used to analyse baseline clinical and treatment characteristics. Kaplan–Meier methods were used to determine iDFS and OS and then log rank tests were used to describe differences between hormone receptor-positive and triple negative breast cancer. Multivariable Cox proportional hazards models were constructed to examine the associations between clinical characteristics and survival outcomes. We included age categories (<50/50–59/> 60 years), hormone receptor status (ER and/or PR positive vs triple negative breast cancer), lymphovascular invasion, grade (I/II vs III), AJCC stage (I/II), CCI score (0/1/2), BMI (normal and underweight, overweight, obese). The prognostic impact of these clinical-pathologic characteristics has been reported in prior studies [27–30]. Due to low number of patients with BMI <18.5 and grade I tumours, normal and overweight, and grade I/II tumours were categorized together, respectively. All statistical tests used in this study were two-sided and the significance level was defined a priori as <0.05. The analyses were performed using Stata statistical software (Stata Corp. 2013. Release 13. College Station, TX).

3. Results

3.1. Patient characteristics

We identified a total of 715 patients with node negative breast cancer who were planned for non-anthracycline based adjuvant chemotherapy with DC. Of these, 58 patients were excluded due to HER2-positive disease and concomitant administration of trastuzumab (32.8%), locoregional recurrent cancer prior to administration of DC (25.9%), and subsequent switch to anthracycline-based adjuvant chemotherapy (19.0%) (Fig. 1). In the final cohort of 657 patients, the median age at diagnosis was 53 years (interquartile range, 26–73 years) and approximately one-fourth of the patients were older than 60 years. While 99.7% of patients were women, two patients were men (0.3%).

Breast conserving surgeries were performed in 59.2% patients and mastectomies in 40.8%. While more than half of the patients (58.6%) had a tumour size of greater than 2 cm to 5 cm, around one-third had a tumour 2 cm or smaller. The most common histological subtype was invasive ductal cancer (76.4%) while lobular and mixed histologies were reported in 6.2% and 14.6% patients, respectively. There were 468 patients (71.2%) with hormone receptor-positive tumours and 189 (28.8%) had triple negative disease. While three-fourths of the patients had MBR grade III tumours, those with grade I and II breast cancer accounted for 4.0% and 21.2%, respectively. Lymphovascular invasion was present in 18.9% of tumours, although data was not available for one-third of histopathology specimens. Post-operative radiotherapy was administered in 60.4% of the patients.

We compared the clinical and pathological characteristics of patients with hormone receptor-positive tumours and those with triple negative breast cancer. The age at diagnosis was similar in both groups (52 vs 54 years, P = 0.116). While triple negative breast cancers were more likely to be grade III (92.6% vs 67.7%, P < 0.001), hormone receptor-positive tumours were more likely to be AJCC stage II (69.0% vs 43.4%, P < 0.001) and have lymphovascular invasion (32.8% vs 17.5%, P = 0.002). Thus, the selected population represented higher risk hormone receptor-positive tumours and lower risk triple negative breast cancer.

With regards to comorbid medical conditions, 14.6% and 8.5% of the patients had a CCI score of one and more than one, respectively. Of note, one-third of patients were overweight and a similar proportion were obese (Table 1).

3.2. Treatment details

Overall, 95.6% of the patients completed the planned adjuvant chemotherapy with four cycles of DC. Twenty-nine patients (4.4%) discontinued chemotherapy after receiving one (1.2%), two (1.7%) or three (1.5%) cycles, respectively. In terms of prophylaxis for febrile neutropenia, oral ciprofloxacin was administered in 54.3% patients, 10.5% received prophylactic growth factor support, and 4.3% received both (Supplementary Table 1).

3.3. Survival outcomes

At a median follow-up of nine years, 125 patients developed an iDFS event, which included 70 distant metastases and 29 new primary cancers (Table 2). The 4-year, 5-year and 9-year iDFS rates were 91.0%, 88.4% and 80.5%, respectively. Likewise, there were 79 deaths, of which 55 were related to breast cancer. The 4-year, 5-year and 9-year OS rates were 95.5%, 92.9% and 88.0%, respectively. Likewise, there were 79 deaths, of which 55 were related to breast cancer. The 4-year, 5-year and 9-year OS rates were 95.5%, 92.9% and 88.0%, respectively. Common sites of distant metastases included bone (25.7%), lung (24.3%) and liver (11.4%). Common new primary cancer sites included ovary and fallopian tube (24.1%), endometrium (17.2%) and colorectum (10.3%).

3.4. Survival outcomes by hormone receptor status

We compared the iDFS and OS rates between patients with hormone receptor-positive tumours and triple negative breast cancer. The 4-year iDFS rates were 91.3% in hormone receptor-positive breast cancer patients compared with 90.3% in those with triple negative breast cancer. The corresponding 9-year iDFS rates were 80.7% and 80.0%, respectively (Fig. 2A). The observed hazard ratio (HR) was 0.98 (95% confidence interval [CI], 0.66–1.45; P = 0.913).

Likewise, the 4-year OS rates were 96.1% and 94.2%, and 9-year
OS rates were 89.4% and 84.6% in patients with hormone receptor-positive and triple negative breast cancer, respectively (Fig. 2B). The observed HR was 1.28 (95% CI, 0.80–2.03; P = 0.304).

3.5. Associations of clinical characteristics with survival outcomes

We constructed multivariable Cox proportional hazards models to determine the associations of clinical characteristics with iDFS and OS. Presence of lymphovascular invasion (HR, 2.17; 95% CI, 1.36–3.45; P = 0.001) and grade III tumour (HR, 2.15; 95% CI, 1.09–4.21; P = 0.026) predicted worse iDFS (Fig. 2C). Similarly, grade III tumour (HR, 3.15; 95% CI, 1.18–8.45; P = 0.022) was significantly associated with worse OS while a trend was observed for lymphovascular invasion (HR, 1.79; 95% CI, 0.97–3.32; P = 0.063) (Fig. 2D). However, age category, hormone receptor status, stage, BMI and CCI score were not related to iDFS (Table 3).

4. Discussion

In this real-world study of patients with node negative breast cancer treated with four cycles of DC chemotherapy, the 9-year iDFS and OS rates were 80.5% and 88.0%, respectively. Higher grade tumours and those with lymphovascular invasion were associated with worse survival. Of note, there was no significant difference in survival outcomes of patients with hormone receptor-positive and triple negative breast cancer.

In the ABC group of trials, the 4-year iDFS rate was 88.2% in patients who received six cycles of DC [14]. Sixty percent of patients included in their pooled analysis were node positive. However, their subgroup analyses for node negative patients demonstrated 4-year iDFS rate of 87.0% for those with triple negative disease and 94.2% for those with hormone receptor-positive breast cancer. The corresponding 4-year iDFS rates in our patients were reassuringly similar at 90.4% and 91.3%, respectively. While the age distribution and proportion of patients with triple-negative breast cancer in our study are quite similar to those of the ABC trials, approximately three-fourths of our patients had MBR grade III tumours as compared with their 51%. Further, the median follow-up of the combined ABC trials was 3.3 years and 9.0 years in our study.

In contrast to the ABC trials, more patients enrolled in the PlanB trial were node negative. Further, there was an interim protocol amendment to exclude patients with hormone receptor positive breast cancer with pathological involvement of 0–3 lymph node, who had a recurrence score of 11 or lower on OncotypeDX testing. PlanB did not report on survival outcomes by nodal status but we can make some broad comparisons with our study results. In PlanB, amongst patients who received six cycles of DC, 5-year DFS and OS rates were 89.9% and 94.7% [17]. The corresponding rates in our study were again, reassuringly similar at 88.4% and 92.9%, respectively. Despite inclusion of node positive patients, the population in PlanB had otherwise more favourable clinical risk as exemplified by 57.5% patients with pT1 tumour and only 18.6% patients with triple-negative breast cancer. In our study, 38.4% had pT1 tumour, while 57.5% patients with pT1 tumour and only 18.6% patients with triple-negative breast cancer treated with chemotherapy were prescribed DC for at least four cycles. For our patients with hormone receptor-positive breast cancer, 9-year iDFS and OS rates were 80.7% and 89.4%, respectively.

### Table 2

| Type of relapse                                      | Number | Percent |
|-----------------------------------------------------|--------|---------|
| Ipsilateral breast only                             | 5      | 4       |
| Ipsilateral axillary nodes only                     | 8      | 6.4     |
| Ipsilateral breast and axillary nodes               | 2      | 1.6     |
| Ipsilateral chest wall only                         | 1      | 0.8     |
| Ipsilateral chest wall and axillary nodes           | 1      | 0.8     |
| Contralateral breast ± nodes                        | 9      | 7.2     |
| Metastatic only                                     | 55     | 44      |
| Local-regional and metastatic                       | 15     | 12      |
| New primary cancer                                  | 29     | 23.2    |
|                                                    | 125    | 100     |
These rates are somewhat lower than 84.3% and 93.8% reported in patients with intermediate recurrence score who received chemoendocrine treatment in the TAILORx trial. On the other hand, our patients fared better compared to TAILORx patients with high recurrence score who received chemoendocrine treatment with respect to 9-year iDFS at 75.7% with OS similar at 89.3% [26].

Publicly funded gene expression profile testing was not available in our jurisdiction until 2014 but high-risk classic pathology characteristics were common as exemplified by 74.9% patients with grade III tumours.

**Table 3**
Multivariable Cox regression model for invasive disease free survival and overall survival.

| Variable | Invasive disease free survival | Overall survival |
|----------|-------------------------------|-----------------|
|          | Hazard ratio                  | 95% confidence interval | P-value | Hazard ratio | 95% confidence interval | P-value |
| **Age category** | | | | | | |
| <50      | Ref                           | 1.26             | 0.74–2.14          | 0.401 | 1.73             | 0.82–3.68          | 0.153 |
| 50–59    | 1.33                          | 0.61–2.07        | 0.700             | 0.401 | 1.82             | 0.83–4.00          | 0.156 |
| ≥ 60     | 2.17                          | 1.36–3.45        | 0.001             | 0.001 | 1.79             | 0.97–3.32          | 0.063 |
| **Hormone status** | | | | | | |
| ER/PR+   | Ref                           | 1.23             | 0.72–2.09          | 0.442 | 1.29             | 0.66–2.50          | 0.458 |
| TNBC     | No                            | 2.17             | 1.36–3.45          | 0.001 | 1.79             | 0.97–3.32          | 0.063 |
| **Grade** | | | | | | |
| I/II     | Ref                           | 2.15             | 1.09–4.21          | 0.026 | 3.15             | 1.18–8.45          | 0.022 |
| III      | 1.48                          | 0.90–2.43        | 0.122             | 0.122 | 1.72             | 0.90–3.27          | 0.099 |
| **Stage** | | | | | | |
| I        | Ref                           | 1.48             | 0.90–2.43          | 0.122 | 1.72             | 0.90–3.27          | 0.099 |
| II       | 0.57                          | 0.33–1.97        | 0.623             | 0.623 | 0.91             | 0.30–2.77          | 0.865 |
| III      | 0.8                            | 0.27–1.21        | 0.141             | 0.141 | 1.07             | 0.48–2.39          | 0.871 |
| **CCI score** | | | | | | |
| 0        | Ref                           | 0.8              | 0.33–1.97          | 0.623 | 0.30             | 0.30–2.77          | 0.865 |
| 1+       | 0.57                          | 0.33–1.97        | 0.623             | 0.623 | 0.91             | 0.30–2.77          | 0.865 |
| **BMI**  | | | | | | |
| Normal   | Ref                           | 1.03             | 0.58–1.84          | 0.507 | 1.02             | 0.47–2.22          | 0.952 |
| Overweight | 0.8                        | 0.27–1.21        | 0.141             | 0.141 | 1.07             | 0.48–2.39          | 0.871 |
| Obese    | 1.03                          | 0.58–1.84        | 0.507             | 0.507 | 1.02             | 0.47–2.22          | 0.952 |

ER: Estrogen Receptor; PR: Progesterone Receptor; TNBC: Triple Negative Breast Cancer; LVI: Lymphovascular invasion; CCI: Charlson Comorbidity Index; BMI: Body Mass Index.
Histological grade was the only tumour characteristic significantly associated with iDFS and OS in our study. Although subject to inter-pathologist variability in assessment, MBR grade has been extensively validated as a clinical prognostic marker in patients with node negative breast cancer [31–33]. In resource constrained settings, where genomic testing is not available and not publicly funded, the MBR grade is used extensively as one of the clinical markers to guide the role of adjuvant chemotherapy in hormone-receptor-positive node negative breast cancer [34,35]. Likewise, lymphovascular invasion was significantly associated with worse iDFS and a trend was observed with OS. Existing literature suggests a prognostic value of lymphovascular invasion in node-negative breast cancer [36–38]. Of note, we did not find a significant difference in iDFS and OS of patients with hormone receptor-positive breast cancer and triple negative breast cancer, although, this finding should be interpreted with caution. Our patients with hormone receptor-positive breast cancer were selected to receive adjuvant DC chemotherapy based on the known clinical and pathologic factors associated with worse prognosis, including grade and lymphovascular invasion, in addition to consideration of younger age and larger tumour size. Further, patients with triple-negative breast cancer treated with sequential or concurrent anthracycline and taxane chemotherapy were not included in this study. Amongst triple negative patients, those prescribed DC may have been clinically lower risk. Further, the subgroups of patients with hormone receptor-positive and triple negative breast cancer were neither randomized, nor numerically balanced.

Seven patients developed a subsequent ovarian or fallopian tube cancer on follow-up. Although we did not have access to family history and genetic information on our patients, this finding raises concern for deleterious germline BRCA1 or BRCA2 mutations and potential missed opportunities for timely genetic testing and risk-reducing procedures. At least two of these patients would have met genetic testing criteria in the era considered based on age <50 and diagnosis of triple negative breast cancer. Further, at least four of these patients would have met current criteria based on age <65 and diagnosis of triple negative breast cancer, validating a change in our guidelines.

This study was limited by its retrospective design. The decision of offering non-anthracycline based adjuvant chemotherapy was based on the provincial guidelines and discussion of the treating oncologists with patients. Moreover, genomic risk tools like the validated a change in our guidelines.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data statement
The data can be shared with the journal for review, if needed.

Declaration of competing interest
None declared.

Acknowledgements
Many thanks to Connell Refo for writing and executing the morbidity algorithm to generate CCI score.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.breast.2020.08.002.

References
[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. https://doi.org/10.3322/caac.21492.
[2] Dabbs DK. Breast cancer control in Canada n.d.:120.
[3] Street W. Breast cancer facts & figures 2017-2018 n.d.:64.
[4] Female Breast Cancer Subtypes – Cancer Stat Facts. SEER n.d. https://seer.cancer.gov/statfacts/html/breast-subtypes.html (accessed May 22, 2020).
[5] Leclerc A-F, Jerusalem G, Devos M, Crielard J-M, Maquet D. Multidisciplinary management of breast cancer. Arch Public Health 2016;74. https://doi.org/10.1186/s13901-016-0163-7.
[6] Minckwitz G von, Loibl S. Evolution of adjuvant chemotherapy for breast cancer. Lancet 2015;385:1812–4. https://doi.org/10.1016/S0140-6736(14)62248-8.
[7] Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Orthod 1991;9:2134–40. https://doi.org/10.1200/JCO.1991.9.12.2134.
[8] Bonneterre J, Roche H, Kerbrat P, Brémond A, Fumoleau P, Namer M, et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French adjuvant study group 05 randomized trial. J Clin Orthod 2005;23:2686–93. https://doi.org/10.1200/JCO.2005.05.059.
[9] Budman DR, Berry DA, Cirrincione CT, Henderson, Wood WC, Weiss RB, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Canc Inst 1998;90:1205–11. https://doi.org/10.1093/jnci/90.16.1205.
[10] Henderson IC, Berry DA, Dernst GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in the adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Orthod 2003;21:976–83. https://doi.org/10.1200/JCO.2003.02.063.
[11] Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717. https://doi.org/10.1016/S0140-6736(05)66344-0.
[12] Azim HA, Aminababa E de, Colozza M, Bines J, Piccart MJ. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol 2011;22:1399–47. https://doi.org/10.1093/annonc/mdq083.
[13] Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant chemotherapy for operable breast cancer. J Clin Orthod 2006;24:5381–7. https://doi.org/10.1200/JCO.2006.06.5391.
[14] Blum JL, Flynn PJ, Yother GS, Asmar L, Geyer CE, Jacobs SA, et al. Anthracyclines in early breast cancer: the ABC trials—USOR 06-050, NSABP B-46-U/SOR 07132, and NSABP B–49 (NRG, Oncology). J Clin Orthod 2017;35:2647–55. https://doi.org/10.1200/JCO.2016.71.4147.
[15] Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja S, McIntyre KJ, et al. Docetaxel with cyclophosphamide is associated with an overall survival
benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology research trial 9735. J Clin Oncol 2009;27:1177–83. https://doi.org/10.1200/JCO.2008.18.4028.

[16] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432–44. https://doi.org/10.1016/S0140-6736(11)61625-5.

[17] Nitz U, Gluz O, Clemens M, Walter W, Reimer T, Nuding B, et al. West German study PlanB trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Orthod 2019;37:799–808. https://doi.org/10.1200/JCO.18.00028.

[18] Eisen A, Fletcher GG, Gandhi S, Mates M, Freedman OC, Dent SF, et al. Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. Curr Oncol 2015;22:567–81. https://doi.org/10.3747/cjo.22.2320.

[19] Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:1184–220. https://doi.org/10.1093/annonc/mdz173.

[20] National Comprehensive Cancer Network. Breast Cancer (Version 4.2020) n.d. https://www.nccn.org/professionals/physician_gls/default.aspx#breast (accessed May 21, 2020).

[21] Adjuvant Systemic Therapy for Early Stage (Lymph Node Negative and Lymph Node Positive) Breast Cancer n.d. https://www.albertahelthservices.ca/info/cancerguidelines.aspx (accessed May 21, 2020).

[22] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453–7. https://doi.org/10.1016/S0140-6736(07)61602-X.

[23] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373–83. https://doi.org/10.1016/0021-9681(87)90171-8.

[24] Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995;854:1–452.

[25] Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, et al. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Canc Res 2017;19:58. https://doi.org/10.1186/s13006-017-0852-3.

[26] Altmann E, Strieter J, Geisler D, Brestgen M, Perren A, et al. Biomarkers in breast cancer: a consensus statement by the German breast cancer society OR (France): PREDICT breast cancer prog nostic signi fi cant of Nottingham histological grade and its components in early (pTINOM0) breast carcinoma. J Clin Pathol 2002;55:88–92.

[27] Rakha EA, El-Sayed ME, Lee AHS, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic signifi cance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008;26:3153–8. https://doi.org/10.1200/JCO.2007.15.5986.

[28] Braithwaite D, Moore DH, Satariano WA, Kwan ML, Hiaty RA, Kromkne C, et al. Prognostic impact of comorbidity among long-term breast cancer survivors: results from the LACE study. Cancer Epidemiol Biomark Prev 2012;21:1115–25. https://doi.org/10.1158/1055-9966.EPI-11-1228.

[29] Bercz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam C-M, et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 2004;15:875–84. https://doi.org/10.1093/annonc/mdn222.

[30] Colomer R, Aranda-López I, Albarell J, García-Caballero T, Ciruelos E, López-García MA, et al. Biomarkers in breast cancer: a consensus statement by the Spanish society of medical Oncology and the Spanish society of pathology. Clin Transl Oncol 2018;20:815–26. https://doi.org/10.1007/s12094-017-1800-5.

[31] Frikovic-Grazio S, Bracco M. Long term prognostic value of Nottingham histological grade and its components in early (pTINOM0) breast carcinoma. J Clin Pathol 2002;55:88–92.